Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide Dose-escalation Regimens in Type 2 Diabetes (SUSTAIN SWITCH)
NCT04287179Phase 3Withdrawn
- Sponsor
- Novo Nordisk
- Start
- Mar 2020
- Primary completion
- Nov 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in glycosylated haemoglobin at 12 weeks. Planned start Mar 2020; status: withdrawn.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04287179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04287179.